183500-72-3

Basic information

• Product Name: Benzonitrile, 4-[(5-formyl-2-methyl-1H-imidazol-1-yl)methyl]-
• CAS NO: 183500-72-3
• Molecular Formula: C13H11N3O
• Molecular Weight: 225.25
• Mol File: 183500-72-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 4-[(5-formyl-2-methyl-1H-imidazol-1-yl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-[(5-formyl-2-methyl-1H-imidazol-1-yl)methyl]-(183500-72-3)
• EPA Substance Registry System: Benzonitrile, 4-[(5-formyl-2-methyl-1H-imidazol-1-yl)methyl]-(183500-72-3)

Safety Data

• Hazardous Substances Data: 183500-72-3(Hazardous Substances Data)

Upstream product

• 17201-43-3 4-cyanobenzyl bromide 
• 35034-22-1 2-methyl-1H-imidazole-4-carboxaldehyde 
• 183500-71-2 4-bromo-1-(4-cyanobenzyl)-2-methylimidazole-5-carboxaldehyde 
• 68-12-2 N,N-dimethyl-formamide 
• 35034-22-1 2-methylimidazole-4⁽⁵⁾-carbaldehyde 
• 288-32-4 1H-imidazole 

Downstream Products

• 1230794-76-9 1-(4-cyanobenzyl)-5-chloromethyl-2-methylimidazole hydrochloride salt 
• 291751-35-4 1-[1-(4-cyanobenzyl)-2-methylimidazol-5-ylmethyl]piperazine 
• 258848-39-4 4-{5-[(4-benzenesulfonyl-3-methyl-phenylamino)-methyl]-2-methyl-imidazol-1-ylmethyl}-benzonitrile 
• 258848-37-2 4-{5-[(4-benzenesulfonyl-phenylamino)-methyl]-2-methyl-imidazol-1-ylmethyl}-benzonitrile 
• 497847-88-8 4-[3-(4-cyano-benzyl)-2-methyl-3H-imidazol-4-ylmethyl]-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

INHIBITORS OF PRENYL-PROTEIN TRANSFERASE

The present invention comprises piperazine/piperazinone-containing compounds having multicyclic ring system substituents on one of the piperazine/piperazinone nitrogens, which inhibit prenyl-protein transferases, including farnesyl-protein transferase and geranylgeranyl-protein transferase type I. Such therapeutic compounds are useful in the treatment of cancer

INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras